Notably, the IR-A is a dual receptor for both insulin and insulin like growth factor 2 (IGF2), and when overexpressed in cancer cells may mediate the effects of locally produced, autocrine and/or paracrine IGF2 as well as the effects of circulating insulin, particularly in insulin-resistant patients with chronic hyperinsulinemia [8,9]. The gene discussed is IGF2; the disease is cancer.